Protein intake in patients with colorectal or lungcancer when receiving a nutritional supplement

No registrations found.

Ethical review Positive opinion **Status** Suspended

Health condition type -

Study type Interventional

Summary

ID

NL-OMON27071

Source

Nationaal Trial Register

Brief title PROTEOS

Health condition

Colorectal and lungcancer

Sponsors and support

Primary sponsor: Nutricia Research B.V.

Uppsalalaan 12

3508 CT Utrecht, the Netherlands

Source(s) of monetary or material Support: Nutricia Research

Intervention

Outcome measures

Primary outcome

To assess protein intake at the end of the first treatment cycle

1 - Protein intake in patients with colorectal or lungcancer when receiving a nutrit ... 13-05-2025

Secondary outcome

- Proportion of subjects with a protein intake above the lower limit of the ESPEN recommendations for protein intake
- Body weight

Study description

Background summary

study ended prematurely due to COVID. No summary available.

Study objective

a higher protein intake at the end of the first treatment cycle in patients with CRC or NSCLC undergoing first line treatment with chemo-, concurrent chemoradio- or immunotherapy who are receiving two servings of test product daily and who completed the study until the end of the first treatment cycle compared with standard of care.

Study design

Visits consist of: Screening, Baseline, Randomization, 1st day of each cycle, week 12 visit, week 13 follow up phone call.

Some questionnaires and diaries must be completed at home during the 13 week period. Timing depends on the treatment (2, 3 or 4 week treatment schedule)

Intervention

Duration of intervention: approximately 13 weeks

Intervention group: receiving two units of test product per day for oral intake for a period of approximately 13 weeks.

Control group: receiving standard of care, ie nutritional support as regularly provided by the hospital,

Contacts

Public

Nutricia corine vlot PO Box 80141

Utrecht 3508 CT The Netherlands +31650292055

Scientific

Nutricia corine vlot PO Box 80141

Utrecht 3508 CT The Netherlands +31650292055

Eligibility criteria

Inclusion criteria

- 1. Histologically proven CRC stage IIB, III or IV or histologically or cytologically proven NSCLC stage III or IV
- 2. Eligible and scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment with a planned duration of at least 12 weeks
- 3. Performance status Eastern Cooperative Oncology Group (ECOG) score 0 or 1
- 4. Age ¡Ý 18 years
- 5. Written informed consent

Exclusion criteria

- 1. Scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment starting ¡Ü4 days after randomization
- 2. Received >10 doses of radiotherapy within 2 months prior to the study
 - 3 Protein intake in patients with colorectal or lungcancer when receiving a nutrit ... 13-05-2025

- 3. Weight loss >10% in the last 6 months
- 4. Body Mass Index < 20.0 kg/m2
- 5. Life expectancy < 3 months
- 6. Prescription of oral nutritional supplementation (ONS) before start of first line treatment based on hospital; standard practice
- 7. Presence of ileostoma or ileal pouch
- 8. Contra-indications to oral feeding, high protein nutrition or to the test product (including galactosaemia) in the opinion of the investigator
- 9. Known pregnancy or lactation
- 10. Current alcohol or drug abuse in the opinion of the investigator
- 11. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
- 12. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

Recruitment

NL

Recruitment status: Suspended

Start date (anticipated): 01-10-2018

Enrollment: 126

Type: Anticipated

4 - Protein intake in patients with colorectal or lungcancer when receiving a nutrit ... 13-05-2025

IPD sharing statement

Plan to share IPD: No

Ethics review

Positive opinion

Date: 02-10-2018

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL7297 NTR-old NTR7506

Other Nutricia: MPR16TA06151

Study results